Brown, T. J., Ruan, P., Jones, A. L., Verma, N., Porembka, M. R., Badiyan, S., Wang, S. C., Sanford, N. N., Kazmi, S. M. A. (2025). FOLFIRI-ramucirumab (FOLFIRI-Ram) versus ramucirumab-paclitaxel (Ram-Pac) in the second line (2L) for patients with advanced upper gastrointestinal (UGI) cancer: A real-world propensity-score matched analysis of survival.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.377